Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNZ-2591 in Prader-Willi Syndrome
NCT05879614Phase 2Withdrawn
- Sponsor
- Neuren Pharmaceuticals Limited
- Start
- Sep 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of NNZ-2591 in Prader-Willi syndrome (PWS), sponsored by Neuren Pharmaceuticals Limited. Planned start Sep 2023; status: withdrawn.
02
Drugs
NNZ-2591
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT05879614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879614.